IGF‐1 treatment activates IGF/IGF‐1R signaling in HBV‐positive HCC cells, increasing expression of cancer stemness markers like nanog homeobox (NANOG) and octamer‐binding transcription factor 4 (OCT4). The gene discussed is IGF1R; the disease is hepatocellular carcinoma.